WASHINGTON--(BUSINESS WIRE)--April 5, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - News) announced today that pre-clinical results from its insulin-like growth factor-1 receptor (IGF-1R) program were featured as part of a media program on molecular targeted therapies sponsored by the American Association of Cancer Research (AACR) during its annual meeting in Washington, DC held April 1-5, 2006. As highlighted in today’s briefing, the research findings demonstrated that OSI’s compound blocked the ability of IGF-1R to activate molecular signaling pathways within tumor cells, resulting in the inhibition of tumor growth. IGF-1R has been viewed as an important therapeutic target due to its involvement in the growth and proliferation in a variety of human cancers, including colorectal, non-small cell lung, breast and ovarian cancers. However, the development of small molecules that effectively block IGF-1R signaling and provide selectivity versus the closely related insulin receptor has proven to be a difficult challenge.
